C-JRLQEnclear Therapies
CSF delivery, precision dosing, neurotechnology
clearingdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JRLQ
C-JRLQC-JRLQCSF delivery, precision dosing, neurotechnology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Enclear Therapies CSF delivery, precision dosing, neurotechnology
EnClear Therapies aims to improve and extend the lives of patients with CNS-related disease. Its EnTrega CSF Platform uses controlled, continuous, personalized CSF delivery and monitoring to optimize CNS therapeutic dosing while reducing peripheral toxicity and severe side effects. The company is leading with neuro-oncology and ENC006 for leptomeningeal carcinomatosis while seeking partnerships in neurodegenerative, lysosomal storage, autoimmune, and epilepsy indications.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Enclear Therapies — Early mechanism · Lower middle. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic